· rebuilt nightly from public records
Signal Sheet
Headquartered in New York, New York, TNF Pharmaceuticals is a publicly listed in vitro & in vivo diagnostic substances company, founded 2023. It raised $7M in Sep 2025 and its filings name 7 officers. Everything below links to the record it came from.
The easy button for new customers
Lakewave's AI keeps accounts like this one coming. Your pipeline refills while you sleep.
Every night it scans funding, filings, new officers, hiring, contracts, permits and bids, finds the accounts that fit what you sell, and delivers each with outreach and a pursuit plan. Just need a list? Its AI waterfall builds one with verified, reachable contacts.
The roles that matter for a seller right now. Names on this page come from SEC filings or the company's own announcements. Contacts you find with a free trial are verified before you see them. How we source names
| Role | Contact | Source | Why they matter now |
|---|---|---|---|
| Executive Officer | Ian Rhodes | SEC filing, Sep 2025 | Named officer in the filing; part of the buying group |
| Executive Officer | Joshua Silverman | SEC filing, Sep 2025 | Named officer in the filing; part of the buying group |
| Executive Officer | Mitchell Glass | SEC filing, Sep 2025 | Named officer in the filing; part of the buying group |
| Chief Technology Officer | Christopher Schreiber | SEC filing, Sep 2025 | Technology and tooling decisions |
| Chief Technology Officer | Bruce Bernstein | SEC filing, Sep 2025 | Technology and tooling decisions |
| Chief Technology Officer | Bill J. White | SEC filing, Sep 2025 | Technology and tooling decisions |
| Chief Technology Officer | Stephen Friscia | SEC filing, Sep 2025 | Technology and tooling decisions |
Signed a material agreement
Corporate eventOfficer or director change
New leadershipEquity raise reported to the SEC, Sep 2025. Money arrives before the spending plan does.
CapitalThe most recent events first, refreshed every night. Each links to the record it came from.
| When | What happened | Kind | Source |
|---|---|---|---|
| Sep 14, 2026 | Signed a material agreement | Corporate event | SEC filing |
| Sep 14, 2026 | Officer or director change | New leadership | SEC filing |
| Sep 10, 2026 | Officer or director change | New leadership | SEC filing |
| Sep 2, 2025 | Raised $7M in equity from 12 investors | Capital | SEC filing |
Lakewave finds the right people at TNF Pharmaceuticals, checks every address against the mail server before you see it, and drafts a first email for each, which you review and send from your own inbox.
Try it on TNF Pharmaceuticals with a free trial →| Headquarters | New York, New York, per the filing address |
| Industry group | In Vitro & In Vivo Diagnostic Substances |
| Founded | 2023, DE |
| Ownership | Listed company |
| Raise history | $7M (Sep 2025) |
Yes. TNF Pharmaceuticals reported a $7M equity raise to the SEC on Sep 2, 2025 with 12 investors.
The company's SEC filing, Sep 2025 names Ian Rhodes (Executive Officer) among its officers.
New York, New York, per the address on its SEC filing.
Select the accounts and territory you sell to and get dated reasons for every company: new budget, new leaders, new hires, with who to reach and a first draft for each contact.
Start your free trialCompiled from public records and refreshed nightly; last updated Nov 16, 2026. Facts are as the SEC, the company's careers page or the company's own announcements published them. Check the source before acting. See something wrong? Tell us and we will correct it.